Baricitinib for Acute Exacerbation in Idiopathic Interstitial Pneumonias: A Preliminary Study Using Propensity Score...

Area of Science:

• Pulmonology
• Pharmacology
• Immunology

Background:

• Acute exacerbation of interstitial lung disease (AE-ILD) is a critical condition with limited therapeutic options.
• Janus kinase (JAK) inhibitors, including baricitinib, are emerging as potential treatments for severe interstitial lung diseases (ILDs).

Purpose of the Study:

• To evaluate the efficacy and safety of baricitinib in patients experiencing AE-ILD associated with idiopathic interstitial pneumonias (IIPs).

Main Methods:

• A retrospective cohort study compared baricitinib-treated patients with historical controls.
• Propensity score matching (PSM) was used to balance groups based on age, oxygenation, and fibrosis.
• Primary outcome was overall survival; secondary outcomes included 90-day survival and adverse events.

Main Results:

• After PSM, 17 patients were analyzed in each group.
• The 90-day survival rate was significantly higher in the baricitinib group (82.4%) compared to controls (52.9%, p=0.049).
• Baricitinib was well-tolerated with mild adverse events; long-term survival did not significantly differ.

Conclusions:

• Baricitinib may enhance short-term survival in AE-ILD patients and was safe in the acute phase.
• The drug's dual JAK1/2 inhibition offers potential anti-inflammatory and anti-fibrotic effects.
• Further prospective research is required to validate findings and explore combination therapies.